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The Modulation by Anthrax Toxins of Dendritic Cell Activation
Ping-Jen (Joe) Chou
ABSTRACT

Bacillus anthracis produces lethal toxin (LT) and edema toxin (ET) and
they suppress the function of LPS-stimulated dendritic cells (DC). Because DCs
respond differently to various microbial stimuli, we compared toxin effects in bone
marrow DCs stimulated with either LPS or Legionella pneumophila (Lp). DCs
were enriched with GM-CSF for 9 days, purified by positive selection, and treated
with toxins for 6h; cells were then stimulated with either LPS or Lp-infection for
24h. DC cytokine production and maturation marker expression varied depending
upon cell stimulus and the mouse strain used. LT but not ET was more toxic for
cells from BALB/c than from C57BL/6 (B6) as measured by 7-AAD uptake;
however, ET suppressed CD11c expression. LT suppressed IL-12, IL-6, and
TNF-α in cells from BALB/c and B6 mice but increased IL-1β in LPS-stimulated
cultures. ET also suppressed IL-12 and TNF-α but increased IL-6 and IL-1β in
Lp-stimulated cells from B6. Regarding maturation marker expression, LT
increased MHCII and CD86 while suppressing CD40 and CD80; ET, on the other
hand, generally decreased marker expression across all groups. We conclude
that the modulation of cytokine production by anthrax toxins is dependent on
v

variables including the source of the DCs, the type of stimulus and cytokine
measured, and the individual toxin tested. However, LT and ET enhancement or
suppression of maturation marker expression is more related to the marker
studied than the cell stimulus or cell source. Anthrax toxins are not uniformly
suppressive of DC function but instead can increase function under defined
conditions.

vi

INTRODUCTION

Anthrax Disease
Bioterrorism. Human anthrax is of interest and concern among the
medical and scientific community around the world particularly after its use as
biological weapon in the U.S. immediately following the attack on the World
Trade Center (61). In the fall of 2001, bioterrorism was achieved each time the
news media alerted the public concerning letters tainted with anthrax spores
distributed through the U.S. postal system. Hoaxes involving envelopes with
harmless powders and threatening notes made the problem even worse for
authorities, and created chaos among Americans as they opened their mail (5).
Brief History. Anthrax is blamed for several devastating plagues that killed
both humans and livestock. The first recorded incident dates back to 1500 B.C.
when the Egyptians described a “plague of boils” affecting the Pharaoh’s cattle.
Scientists eventually named the disease, anthrax, and it emerged in World War I
as a biological weapon due to ease of laboratory production and deadliness via
aerosol dissemination (5, 86). Several countries are believed to have
experimented with anthrax, but its use in warfare has been limited. Prior to the
attack of 9-11, the average natural occurrence in the U.S. is 1-2 cases per year,
and the last reported death is over 25 years ago (5, 158).
1

Bacillus Anthracis
Morphology and Physiology. Bacillus anthracis is the etiological agent of
anthrax. It is a Gram-positive, facultative anaerobic, spore-forming, large bacillus
about 1 – 1.2 μm in width and 3 – 5 μm in length (34, 93). Under conditions of
environmental stress, these bacteria can naturally form spores which can persist
in the soil and survive for decades. Spores can also be formed in culture and in
the tissues and exudates of dead animals, but not in the blood or tissues of living
animals. The endospores are ellipsoidal shaped and located centrally in the
sporangium. They are highly refractile to light and resistant to staining (34, 93).
Epidemiology and Transmission. Anthrax is a major disease threat to
herbivorous animals like cattle, sheep, and to a lesser extent horses, hogs, and
goats (140). In humans, anthrax can occur in three distinct clinical forms:
cutaneous, inhalational (or pulmonary), and gastrointestinal. Cutaneous anthrax
accounts for more than 95% of human cases, and is characterized by large black
skin lesions classically found on hands, forearms, or head. Inhalational anthrax
often results in death due to respiratory distress (pulmonary edema) and
septicemia, and is therefore regarded as the most significant form in biological
warfare. Gastrointestinal anthrax results from ingestion of meat derived from
diseased animals. Because of strict control measures, this form is not seen in
the U.S (93, 140).
Pathogenicity. The principal virulence factors of B. anthracis are encoded
on two virulence plasmids: capsular polypeptide on plasmid pXO2, and anthrax
toxins on pXO1 (34). The bacilli are covered by antiphagocytic, polyglutamic
2

capsule which helps to evade host immunity and mediate the early invasive
stage of infection. The capsule, though nontoxic, functions to protect the
organism against the bactericidal components of serum and phagocytes (93).
Anthrax toxins are a heat-labile, heterogeneous protein complex made up of
three components called protective antigen (PA), lethal factor (LF), and edema
factor (EF) (25, 38, 95). And in binary complexes these proteins form the anthrax
toxins: lethal toxin (LT) = PA + LF and edema toxin (ET) = PA + EF (25, 95).

Anthrax Toxins Effects on Immunity
Entry of Anthrax Toxins. Edema toxin (ET) and lethal toxin (LT) share a
receptor-binding subunit PA but have different catalytic subunits, EF and LF,
respectively. PA facilitates the translocation of either factor across the cell
membrane through receptor-mediated endocytosis (25, 95, 164). PA binds to
surface anthrax-toxin receptors that are ubiquitously expressed on cells and
tissues (164). Upon binding to these receptors – either tumor endothelial marker
8 (TEM8) (15, 17, 155) or capillary morphogenesis protein 2 (CMG2) (129) –
together with the coreceptor low-density lipoprotein receptor-related protein 6
(LRP6) (154), PA becomes the substrate of a furin-like membrane protease. The
cleaved fragments of PA self-associate to form ring-shaped heptamers capable
of binding up to three LF or EF molecules (150). The formation of PA-EF or PALF complexes results in their entry into lipid rafts, followed by their endocytosis
into acidic endosomal compartment (78). The drop to lower pH triggers PA
heptamers to undergo conformational change and form a channel that assists the
3

translocation of LF and EF into the cytosol (25). Once inside the cell, LF is a
zinc-dependent metalloprotease that cleaves most members of the MAPK
kinases family and disrupts intracellular signaling, resulting in pro-inflammatory
response suppression (25, 77, 95). EF is a calcium- and calmodulin-dependent
adenylate cyclase that increases the intracellular concentration of cAMP,
resulting in immune cell modulation (25, 80, 95). Though LT has been shown to
be more toxic than its counter part, it is speculated that these toxins work in
concert to promote disease (8, 142).
Toxin Effects on T Cell and B Cell Immunity. The adaptive immune
response is highly specific for a particular pathogen, and improves with each
successive encounter with the same pathogen. T and B lymphocytes are central
to this branch of immunity because of their antigen-specific nature in recognizing
individual pathogens. T lymphocyte activation requires the activation of MAPK
signaling pathway (35), which is a common target for both toxins. Disruption of
this pathway by LT and ET impairs the T cell receptor (TCR)-dependent T cell
activation and proliferation (27, 44, 123). LT inhibits the activation of Erk1, 2,
p38, and JNK MAPKs (27, 44, 123), while ET blocks all MAPKs except p38
(123). LT and ET together thus suppress cytokine production including IL-2, IL-4,
IFN-γ, TNF-α, and IL-5, and surface marker expression CD69 and CD25 (27, 44,
108, 123). Moreover, this impairment correlates with the inhibition of nuclear
factor of activated T cells (NFAT) and activation protein (AP)-1 which are
downstream transactivators of MAPK activation (123).
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Though activation of antigen-specific B lymphocytes requires the presence
of activated T lymphocytes, LT can also inhibit B cell activation directly by
targeting the MAPK pathway (8). Fang et al. showed that LT inhibits B cell
proliferation and antibody production in vitro and in vivo by the proteolysis of
MAPKKs (45). Their data suggest an effective mechanism through which LT
could attenuate protective humoral immune responses elicited by B. anthracis
(45).
Toxin Effects on Innate Immunity. Innate immunity plays a vital role in
immune surveillance against pathological infectious agents (163). Phagocytic
cells, such as dendritic cells, macrophages and polymorphonuclear neutrophils,
are mediators of innate immunity, and they recognize, phagocytize and eliminate
microbes through induction of the oxidative burst and cytokine expression (8,
126).
Macrophage activation requires the activation of MAPK pathway which
induces downstream biosynthesis of pro-inflammatory cytokines (e.g., TNF-α, IL1β, IL-6), chemoattractants (e.g., IL-8, RANTES), and enzymes (e.g., COX-2,
iNOS) (22, 70, 127). LT has been shown to interfere with this process by
cleaving the amino-terminal extensions of the catalytic domain from six of seven
mitogen-activated protein kinase kinases (MAPKK) (37, 39, 148). In addition, LT
induces killing of macrophages in certain susceptible mouse strains (90, 91),
which has been associated with a region on Chromosome 11 that encodes the
kinesin-like motor protein Kif1c (120, 153). ET is also a potent inhibitor of MAPK
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pathway by catalyzing large amounts of cAMP from ATP; cAMP can interfere
with intracellular signaling at multiple levels (8, 68).
There is less information on neutrophils compared to macrophages;
nonetheless current studies suggest that B. anthracis uses both toxins to evade
killing by these cells (8). In neutrophils, ET and LT inhibit the oxidative burst
elicited by lipopolysaccharide (LPS) and muramyl dipeptide (MDP) (160). In
addition, the increase in cAMP by ET inhibits neutrophils ability to phagocytize
(105, 152); while LT inhibits neutrophils ability to move (chemotaxis) by impairing
its actin filament assembly (40). In monocytes, accumulation of cAMP induced
by ET was shown to block TNF-α production, thus impairing antimicrobial
activities (56).

Toxin Effects on Dendritic Cells (DC)
Biology of DC. DCs are the most efficient antigen-presenting cells and are
central to the integration of innate and adaptive immunity (1, 82, 115, 133). For
participation in innate immunity, DCs express pattern recognition receptors
(PRR) such as the Toll-like receptors (TLR) which allow them to detect within
minutes microbial stimuli as well as tissue damage and necrosis (41). Since the
identification of distinct subsets of DCs, much attention has been given to
understanding the functions of these subpopulations in immune induction and
regulation (62). In this study, we use bone marrow-derived dendritic cells (BMDC) isolated from the tibia and femurs of BALB/c and C57BL/6 (B6) mice.
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Maturation of DC. DCs upon stimulation by microbial antigens go through
a maturation process from immature cells to mature, antigen presenting cells.
Immature DCs are central to innate immunity and are “immunological sensors”
that sample the environment for microbial antigens. Upon sensing antigens,
immature DCs begin to produce cytokines such as IL-12, IL-6, TNF-α, and IL-1β
that contribute to innate and adaptive immunity (see below). As they continue to
mature, DCs migrate to secondary lymphoid organs where they present
processed antigen to naïve T cells to launch an adaptive immune response (1,
82, 133). Maturing DCs express, in addition to cytokines, high levels of adhesion
and co-stimulatory molecules (e.g., CD40, CD80, CD86), as well as MHC II
molecules, which interact with T helper cells (see below) (69). Increasing
evidence suggests that DCs polarize the type of T cell response by expressing a
selective set of T cell-polarizing molecules. For example, DCs exposed to
intracellular bacteria promote T-helper type I (Th1) responses, whereas certain
parasites promote DCs to drive the development of Th2 cells (33, 65).
Surface Markers. Maturing DCs begin to process ingested microbial
antigens into peptide fragments, which are then presented by MHC molecules to
T lymphocytes (53). In addition to increasing the expression MHC molecules,
maturing DCs increase the expression of T cell polarization, co-stimulatory
molecules such as CD80 (B7-1), CD86 (B7-2), ICAM1, etc (26). B7 (CD80,
CD86) proteins are recognized on T cells by CD28 and cytotoxic T lymphocyteassociated antigen 4 (CTLA-4). Interaction of these molecules dictates the
activation and expansion of all effector and regulatory Th cells subsets (21, 52).
7

Another set of molecules that provide co-stimulatory signals is CD40 ligand
(CD40-L) on T cells and CD40 on DCs; expression of CD40 facilitates the
activation of helper T cells (116).
Cytokines. In addition to co-stimulatory molecules, maturing DCs can also
communicate via the release of cytokines. Immature DCs readily secrete IL-12
upon stimulation with microbial antigens such as lipopolysaccharide (LPS) and
viral DNA and dsRNA signaled through the TLR (64, 88). In addition to activating
T cells and cell mediated immunity, IL-12 is well known for contributing to local
inflammation (143). Other proinflammatory and T cell-stimulating cytokines
produced by immature DCs include IL-6, IL-1β, and TNF-α. IL-6 stimulates acute
phase proteins from liver (76) and also is important in the development of Th17
cells (107). IL-1β is important pro-inflammatory cytokine regulating fever and the
acute phase response as well as activating T cells (118). TNF-α is a septic
shock-inducing cytokine that has shown to cause apoptosis in a variety of
immune cells (23, 130) as well as support the development of T helper cells (79).
Toxin Effects on DCs. Several studies designed to examine the effects of
anthrax toxins on immunity have studied their effects on DCs. LT has been
reported to induce necrosis in BALB/c-derived DCs but apoptosis in cells from B6
mice in vitro. DCs from humans are reported to also respond with apoptosis
following LT treatment (3, 8). Agrawal and colleagues were the first to
demonstrate an effect of anthrax toxins on DC function. Using purified LT, they
showed that the function of mouse splenic DCs was compromised in vitro in
terms of LPS-stimulated expression of co-stimulatory molecules and
8

proinflammatory cytokines (1). Additional work by Tournier et al. using bone
marrow-derived DCs instead of splenic DCs showed that both LT and ET could
suppress or enhance cytokine production depending on the cytokine tested, and
concluded the toxins cooperated to suppress the innate immune response (142).
In both studies, the authors proposed that this disruption might impair both innate
and adaptive immunity to B. anthracis infection; it was also proposed that the
toxins might not only alter immunity to anthrax but predispose affected individuals
to other diseases due to immune modulation (135).

Microbial Stimulation
Lipopolysaccharide (LPS). Studies examining the effect of anthrax toxins
on DC function have used DCs stimulated with either lipopolysaccharide (LPS) or
B. anthracis organisms. LPS is a major component of the Gram-negative
bacterial cell envelope, which elicits potent proinflammatory responses in
immune cells. LPS consists of three components; Lipid A, Core polysaccharide,
and O antigen. This endotoxin activates B cells and induces macrophages and
other cells to release IL-1, IL-6, TNF-α, among other cytokines (6, 31, 43, 106).
LPS can also induce DC maturation in vitro and in vivo, resulting in increased
expression of co-stimulatory molecules and production of proinflammatory
cytokines that influence the subsequent immune response (1, 63, 73, 142).
Legionella pneumophila (Lp). Lp is an intracellular, Gram-negative
bacterial pathogen causing Legionnaires’ disease (99). Adaptive cellular
immunity plays an important role in host defense to Legionella (84, 102).
9

Legionnaires’ disease is prevalent among immune compromised individuals,
including transplant patients, patients receiving corticosteroids, and patients
suffering from AIDS (72).

Project Significance
It is clear from the evidence so far that anthrax toxins can modulate
immune cell function including DC function. Unfortunately, the effects of the
toxins on DC immune functions are limited only to cells stimulated with either B.
anthracis alone or stimulated with LPS. These initial studies examining only two
methods of DC stimulation offer a limited insight into the immunobiology of these
toxins and therefore we designed studies to compare toxin effects in DCs
stimulated with either LPS or Lp. Comparison of these two stimuli offer the
opportunity to examine toxin effects on DCs stimulated in very different ways in
order to more fully understand the potency of the toxins to modulate DC function
under different conditions. The results obtained from these studies will have
important applications in several different ways. First, because DCs are pivotal
in bridging innate and adaptive immunity, a fuller understanding of the
modulation capabilities of these cells by anthrax toxins will provide greater insight
into the current use of DCs as alternative therapeutics for vaccine development
(132, 159), anti-cancer therapy (47, 100), and other immunotherapy (94). As we
will show below, the toxins enhance and suppress DC function suggesting the
use of these toxins as potential immunosuppressive agents or adjuvants in
immunotherapy (131). Secondly, our understanding of the pathogenesis,
10

prevention, and treatment of anthrax is incomplete. Treatment with oral
ciprofloxacin or doxycycline is effective only to kill the vegetative bacteria (96).
These antibiotics are of limited benefits if a threshold level of anthrax toxin has
already been produced following colonization. The use of antitoxin, such as
antibodies, receptor decoys, translocation inhibitors, LF or EF inhibitors, etc., has
been of major focus and extensive research recently to neutralize toxin effects
(117). However, a full understanding of the immunomodulating potential of LT
and ET, especially as it relates to DC stimulation under varying conditions, is
imperative in the successful management of B. anthracis infected individuals.

11

OBJECTIVES

This project investigates the suppressive nature of anthrax lethal and
edema toxins on activated mouse BM-DC cells. Agrawal et al. have shown
previously the LT suppressive role on LPS-activated splenic DC in vitro (1), while
Tournier’s group in vivo studies has demonstrated ET is suppressive on IL-12
and IFN-γ in LPS-challenged BALB/c and B6 mice (142). Our lab has previously
shown that infection of DCs with Legionella induces a spectrum of cellular
changes consistent with Th1 immune polarization (84, 85, 103). For example, Lp
infection causes an increase in the production of polarizing cytokines such as IL12, IL-6, and TNF-α along with increased MHC class II expression. In addition, in
contrast to LPS stimulation, Lp stimulates DCs through TLR 2 and TLR 9 rather
than TLR 4 (93). The cellular mechanisms mediating these responses to Lp
differ in many ways to those occurring following LPS or B. anthracis stimulation;
therefore, we hypothesize that modulation of DC function by anthrax toxin
treatment will vary significantly in cells stimulated with Lp rather than LPS as in
previous studies. Accordingly, to study further anthrax toxins effects on DC
function, we designed studies to test their effects not only following LPS
treatment but also following infection with Lp. Our data support the conclusion
that anthrax toxins are not uniformly suppressive of DC function but rather
12

modulate function up or down depending on variables such as the function
tested, the stimulus used to activate the DCs such as either LPS or Lp, and the
genetic variation in innate immune response mechanisms in the host cell.

Aim One: To Determine Effects of Anthrax Toxins on DC Maturation
Following Stimulation with Lp infection
The overall aim of this study is to examine the modulating effect of anthrax
toxins on the maturation response of DCs following stimulation with microbial
antigens. The purpose of aim one is to examine the in-vitro immune response of
toxin-treated BM-DC following exposure to L. pneumophila in BALB/c mouse
model. Several experimental parameters need to be considered initially, which
include DC enrichment, toxin concentration, and Legionella survivability in toxintreated DCs. Maturation can be measured by quantitating the expression of
various cell surface markers and cytokines released from the cell. The defining
DC marker is the CD11 lymph node homing receptor (18). GM-CSF is used to
induce myeloid DC progenitor cells from mouse bone marrow to become
immature BM-DCs and then these immature cells can be further matured by
treatment with microbial antigens. We will characterize DC maturation using
commonly described surface markers, CD11c, CD11b, and F4/80 and cytokines
such as IL-12, IL-6, TNF-α, and IL-1β. For toxin concentration, it has been
previously reported that the effective concentration required to suppress DC
cytokine response was in the microgram/ml range (1). One caveat, however,
other studies have shown necrosis and apoptosis of macrophages following toxin
13

exposure (16, 74, 90, 97, 109, 151). Therefore, it is imperative that we determine
the effective concentration of lethal and edema toxins required to modulate the
immune response of Lp-infected DCs without overdosing or killing them. Parallel
to this reasoning, it is just as important to understand how Lp survives in toxintreated DCs. Our lab has previously observed that Lp does not grow inside of
DCs (99, 103); it will be of interest to determine if anthrax toxin treatment
modulates this growth suppressive effect.

Aim Two: To Determine Toxin Effects on Cytokine Production in Response
to LPS and Lp in DCs from BALB/c and C57BL/6 mice.
Several toxin studies using animal models or cell cultures from different
mouse strains have displayed varied functional responses, suggesting the
degree of toxin susceptibility may be dependent upon genetic background (90,
92). To study anthrax toxin specificity, two types of mice will be used: one being
a toxin-susceptible strain, BALB/c, and the other one, toxin-resistant strain, B6.
In addition to this variable, we will also assess DC maturation using LPS and
Legionella infection. Comparison of these two microbial stimuli will provide a
greater understanding of how anthrax toxins modulate DC maturation due to a
variety of stimulating signals. DC maturation will be assessed by the cytokine
response profile of IL-12, IL-6, TNF-α, and IL-1β. In addition, the purity and
viability of the DCs from the various groups will be determined by the expression
of CD11c and the DNA intercalating dye 7-AAD, respectively.
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Aim Three: To Determine Toxin Effects on Surface Marker Expression in
Response to LPS and Lp in DCs from BALB/c and C57BL/6 Mice.
DC maturation can be evaluated by determining the sequential expression
of surface proteins or markers. Previous reports showed a mixed effect of
anthrax toxins on marker expression. For example, In their study on LT treated
splenic DC, Agrawal’s group noted significant inhibition of co-stimulatory
molecules CD80, CD86, and CD40 following LPS stimulation (1). However,
another study using germinating spores showed otherwise; Tournier et al.
claimed that toxins secretion from live B. anthracis did not impair maturation of
DC from BALB/c and B6 mice (142). We will analyze by flow cytometry the
expression of maturation markers MHCII, CD40, CD80, and CD86 from BALB/c
and B6 DC stimulated with either LPS or Legionella as our model of infection.
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MATERIALS AND METHODS

Mice and bacteria
BALB/c and C57BL/6 (B6) were purchased from NCI-Harlan (Fredrick, MD).
They were used at 9 to 13 weeks of age. They were housed and cared for at the
University of South Florida Health Sciences Center Animal Facility, which is fully
accredited by the American Association for Accreditation of Laboratory Animal
Care. A virulent strain of Legionella pneumophila (Lp, M124), serogroup 1
isolate from a case of Legionnaires’ disease at Tampa General Hospital (Tampa,
FL), was cultured on buffered charcoal yeast extract plates for 48h from a
passage 3 stock stored at -80°C. The concentration of bacteria was determined
by spectrophotometer. For infection of DC cultures, see below.

Isolation and Purification of Dendritic Cells
The femurs and tibias were removed from euthanatized mice. The bone marrow
cells were flushed out of the leg bones with buffer RPMI 1640 and
antibiotic/antimycotic solution (Sigma). The red blood cells in the suspension
were lysed using ammonium-chloride potassium, and the cells were
resuspended in RPMI 1640 supplemented with 50μM 2-ME, 10% BGS,
antibiotics, 100mM L-glutamine, and 5ng/ml GM-CSF. Briefly, on day 0, 1 x
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106/ml cells were seeded in 3ml medium in 6-well plates (Costar). On day 1,
non-adherent cells were removed by gentle washing, and the wells were
replaced with fresh medium. On day 3, the wells were replenished with nutrients
by replacing 1 ml of fresh medium. After day 9 in culture, dendritic cells were
loosely attached to culture plates and were easily harvested by gently rinsing for
subsequent use. For further purification by magnetic cell sorting, an
AutoMACS™ Separator Pro (Miltenyi Biotec, France) was used according to the
manufacturer’s protocol. Up to 108 total GM-CSF enriched cells were resuspended in running buffer (PBS plus 0.5%, culture grade bovine serum
albumin, and 0.75 mg/ml EDTA) at room temperature and then incubated with
CD11c Microbeads N418 (Miltenyi Biotec, France) for 15min at 4-8°C. Cells
were re-suspended in buffer (107 cells/ml) and sorted with AutoMACS™
Separator Pro using program “possel” for positive selection.

Anthrax toxin treatment
The recombinant toxin components PA, LF, and EF, purchased from List
Biological Laboratories, Inc. (Campbell, CA), were reconstituted in sterile, 1%BSA in PBS buffer and stored in aliquots at -80°C according to the
manufacturer’s instruction. DCs were preincubated with PA 200ng/ml alone or
with either LF 0.01 – 50ng/ml or EF 0.1 – 50ng/ml for 5h, at 37°C, in complete
RPMI (RPMI 1640 supplemented with 50μM 2-ME, 5% FCS, 100mM Lglutamine). The cells were washed with HBSS, resuspended in culture medium,
and stimulated with either LPS (1μg/ml) or Legionella pneumophila for 24 hours.
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For Legionella infection, DCs in culture medium were infected for 50 min with
viable bacteria at a 10-20:1 ratio (bacteria-to-cells) (Appendix A) and then
washed to remove excess extracellular bacteria. Culture cells and supernatants
were harvested after 18-24 hours (Appendix B) and analyzed for cytokines,
viability, and surface marker expression.

Flow Cytometry Analysis and Cell Viability.
Surface markers were analyzed by flow cytometry. Following treatment and
incubation for 24 hours, DCs were re-suspended to 1 x 106 cells/ml in PBS
containing 2% fetal calf serum, Fc receptors blocked with anti-Fc receptor
FcγRII/RIII antibodies for 15min on ice, stained with FITC- (Fluorescein
Isothiocyanate), PE- (R-Phycoerythrin), and APC- (Allophycocyanin) conjugated
monoclonal antibodies to CD11c, CD40, CD80 (B7.1), CD86 (B7.2), and MHC II
(BD Pharmingen™, San Jose, CA) for an additional 30min. To assess cell
viability, labeled cells were centrifuged, resuspended and incubated for 5min on
ice with 7-amino-actinomycin D (7-AAD) (BD Pharmingen™, San Jose, CA), and
then suspended in 1ml 2% FCS-PBS buffer. Stained cells were analyzed by flow
cytometry using FACSCanto II (Becton-Dickinson, Mountain View, CA) and the
program BD FACSDiva Software v5.0.1 (Becton-Dickinson, Mountain View, CA).
Some data were further analyzed using FlowJo 7 (TreeStar, Inc., San Carlos,
CA) to exclude dead (7-AAD-positive) cells.
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Enzyme-linked Immunosorbent Assay
The proinflammatory cytokines IL-12p40/p70, IL-6, IL-1β and TNF-α were
measured in 24-h DC culture supernatants by ELISA. Medium-bind, 96-well
Costar enzyme immunoassay (EIA) plates were coated with anti-murine IL12p40/p70 (Pharmingen, San Diego, CA) in NaHCO, pH 8.2. After 2h at 37ºC,
the plates were blocked for 1 h at 37ºC. Culture supernatants and serial dilution
of murine IL-12p40/p70 standard (Pharmingen) were added for 1 h, followed by
biotinylated anti-murine IL-12p40/p70 for 1 h, and then Horse Radish Peroxidase
for 30 min. After the substrate TMB (Sigma) was added, plates were allowed to
develop for 15-45 min, and stopped with H2SO4. Units were calculated from the
standard curve, which was performed for each plate. The plates were washed
between each step with two to five changes of nanopure water. IL-6 ELISA was
performed by the same protocol with anti-IL-6 in PBS, biotinylated anti-IL-6
antibody, and recombinant IL-6 for standards. IL-1β and TNF-α ELISA were
coated with anti-IL-1β and anti-TNF-α antibodies respectively in carbonate, pH
9.5. Biotinylated and recombinant antibodies were used accordingly.

CFU Determinations
At 0h, 24h, 48h, and 72h, DC cultures in the 96-well plates were lysed with 0.1%
saponin (Sigma). The lysates were diluted in Hanks balanced salt solution,
plated on BCYE plates, and incubated at 37°C for 72 h. CFU counts were
determined on an AutoCount apparatus (Dynatech Labs, Chantilly, VA).
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Statistical Analysis
The data approximately follow a normal distribution and the observations were
independent to each other; therefore, the real values in ng/ml or pg/ml from any
two groups were compared by one-tailed t-test (unequal variance). Based on the
alpha = 0.05 level, statistical significance is noted by ♦ and * between compared
sample groups where p < 0.05. The values in Figure 1 are expressed as percent
of control wherein the control is the Legionella only (Lp only) treated group.
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RESULTS

Aim One: To Determine Effects of Anthrax Toxins on DC Maturation
Following Stimulation with Lp infection
CD11c Enrichment by GM-CSF and Incubation Time
To determine the optimal time point to harvest quality DCs from bone
marrow cell cultures, DCs collected from day 7, 8 and 9 were analyzed by flow
cytometry for surface markers CD11c, CD11b, and F4/80. The bone marrow cell
cultures were enriched with GM-CSF, an important colony stimulating factor
necessary to drive the DC development from their progenitor cells. Figure 1
shows that as F4/80 expression gradually decreases with incubation time, CD11c
increases its expression from 59% on day 7 to about 77% on day 9. As for
CD11b, it remains a constant 100% expression regardless of collection times.
As cells became more CD11c positive, we also noticed that the population
became more homogenous as indicated by the forward-and-side scatter dot plot.
The subpopulation below the gate gradually diminished every day after day 7.
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20%
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7%

32%

F4/80
20%

CD11b

41%

59%

42%

33%

31%

69%

23%

77%

CD11c

Figure 1. Enrichment of CD11c Cells with Incubation Time
Bone marrow cells isolated from mouse femurs and tibias were cultured for 7, 8,
and 9 days in medium containing GM-CSF 10ng/ml and analyzed by flow
cytometry for expression of F4/80, CD11b, and CD11c. This is a representative
data of 2 experiments.
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Legionella Growth Unaffected by Anthrax Toxin Pretreatment
To determine whether anthrax toxins affect L. pneumophila in DCs, we
monitored the bacterial growth over a period of three days. DCs, in general, do
not support Legionella growth even in permissive A/J mice wherein Legionella
thrives in derived thioglycolate-elicited macrophages (125). In this study, DCs
were preincubated with either LT or ET for 6 hours, infected with Legionella at an
MOI of 10; and CFU counts were determined at 24h, 48h, and 72h post infection.
At time 0h, DCs from all groups demonstrated efficient uptake of bacteria
averaging 50- to 60-thousand colonies (Figure 2). However, regardless of toxin
treatment or not, Legionella growth steadily declined throughout the course of the
3-day period. These data suggest that anthrax toxin does not affect L.
pneumophila intracellular growth.
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Colony Forming Units

Time (Hours)
Figure 2. Intracellular Lp Growth Unaffected by Anthrax Toxin Pretreatment
Dendritic cells from BALB/c mice were infected with L. pneumophila MOI 10:1,
and the cells were washed and incubated for 24, 48, or 72h with or without toxin.
The cells were lysed, and CFU counts were determined. Data are the mean and
standard error of the mean (SEM) of three experiments.
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Modulation by LT and ET of DC Cytokine Production in Response to Lp Infection
It has been reported that LT suppresses cytokine production by splenic
DCs stimulated with LPS and that the effective toxin concentration was in the
microgram/ml range (1). However, other studies involving bone marrow-derived
DCs rather than splenic and stimulated with other stimuli such as B. anthracis
spores, suggested that suppression of cytokine production was not uniformly
observed (142). And, in fact, LT treatment increased certain cytokines as did
treatment with ET (142), suggesting that the toxin effects may differ depending
upon the source of the DC and the cell stimulus used. To extend these studies,
therefore, we examined the effect of various toxin concentrations in bone marrow
DC cultures infected with the intracellular pathogen, Legionella pneumophila (Lp)
(Figure 3 and 4). DCs were cultured and treated with 200ng/ml protective
antigen (PA) for 6 hours and increasing concentrations of either LF (0.01 –
50ng/ml) or EF (0.1 – 50ng/ml) followed by infection with Lp for 50 min. The cells
were washed and resuspended in medium and cultured for an additional 18
hours. Culture supernatants were collected and analyzed by ELISA for IL-12, IL6, IL-1β, and TNF-α. PA treatment alone did not significantly effect cytokine
production; however, LF combined with PA dose-dependently decreased the
production of all four cytokines (Figure 3). EF plus PA treatment also
suppressed IL-12 and TNF-α at 50ng/ml, but significantly increased the
production of IL-6 and IL-1β even at relatively low concentrations (Figure 4).
These toxin effects were attenuated using toxins heated to 56°C for 35 minutes
(Appendix C) confirming previous reports (142) that only active toxins modulate
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cytokines in DCs. These results suggested LT treatment was uniformly more
suppressive when added to Lp-infected DCs while ET was less suppressive and
even capable of enhancing cytokine production depending upon the
concentration of the toxin.
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Figure 3. Lethal Toxin Suppresses Effectively Proinflammatory Cytokines
DC cultures were pretreated for 5-6h with protective antigen (PA) 200ng/ml and
LF at 0.01 – 50ng/ml. The cultures were then infected with Lp for 50 min and
supernatants were analyzed 18h later by ELISA for IL-12p40/p70, IL-6, IL-1β,
and TNF-α. The results are expressed as percentage of the Lp only control and
are the means of six experiments. * p < 0.05, compared to Lp control.
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Figure 4. Edema Toxin Differentially Regulates Proinflammatory Cytokines
DC cultures were pretreated for 5-6h with protective antigen (PA) 200ng/ml and
EF at 0.01 – 50ng/ml. The cultures were then infected with Lp for 50 min and
supernatants were analyzed 18h later by ELISA for the pro-inflammatory
cytokines indicated. The results are expressed as percentage of the Lp only
control and are the means of four experiments. * p < 0.05, compared to Lp
control.
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Aim Two: To Determine Toxin Effects on Cytokine Production in Response
to LPS and Lp in DCs from BALB/c and C57BL/6 mice.
CD11c Purification by CD11c Positive Magnetic Sorting
The reports from most mouse DC studies consider a minimum of 95%
CD11c expression the gold standard for DC purity. Our DCs enriched with GMCSF for 9 days were about 75-80% CD11c positive. To further increase this
percentage, DCs were purified by labeling the cells with anti-CD11c magnetic
nanoparticles for positive selection, then sorting by AutoMACS™ Separator Pro
as described in Materials and Methods. Again the cells were analyzed by flow
cytometry for surface marker CD11c, CD11b, and F4/80. Clearly, the forwardand-side scatter dot plot (Figure 5A) shows the subpopulation from the smaller
gate was completely removed after the selection, leaving a homogenous DC
population in the larger gate. The right panel in Figure 5B shows that the cells
removed were those of CD11c-negative, CD11b-positive, and F4/80-intermediate
population which could likely be DC progenitor cells and macrophages.
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A

B
Non-purified

Non-purified
9%

Purified

28%

1%

46%

F4/80

FSC

24%
C
47%
Purified

48%

52%

5%

94%

CD11b

CD11c

SSC

Figure 5. CD11c Purification by CD11c-Positive Magnetic Sorting
F4/80 and CD11b single positive cells were removed by magnetic sorting by
AutoMACS™ Separator Pro. (A) A scattergram before (non-purified) and after
(purified) the selection. (B) F4/80, CD11b, and CD11c subtypes in non-purified
and purified populations.
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Cytokine Production by Purified versus Non-purified DCs
To determine whether there is any difference in function between DCs that
were about 75% CD11c-positive or “non-purified” and CD11c-sorted cells or
“purified”, we compared the cytokine released from these two populations
following microbial stimulation. Non-purified and purified DCs were either
stimulated with LPS 1μg/ml or infected with Legionella at MOI of 10:1. The
supernatants were collected 24h post stimulation and assayed by ELISA for
proinflammatory cytokines. Figure 6A shows that non-purified DCs produced
more IL-12 than purified ones following LPS stimulation, yet produced about the
same amount following Lp infection. As for IL-6 (Fig. 6B) and TNF-α (Fig. 6D)
production, both populations displayed similar secretion pattern following
microbial stimulation. In terms of IL-1β, LPS was again more potent at inducing
non-purified DCs to release a bit more cytokines than the purified counterpart.
When comparing the cytokine profiles side by side, the general pattern of
cytokine secretion was very similar; and the minor difference seen in IL-12 and
IL-1β was at best half-fold. These data suggest that the 20% difference in
CD11c expression between the purified and non-purified DCs would not have
contributed much difference in function against microbial stimulation. However,
to conform to current standard, DCs tested in subsequent studies were purified
by bead selection.
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Figure 6. Comparison of Cytokine Production by Purified and Non-purified
DC Populations Following Stimulation with Legionella or LPS
Non-purified and purified DCs were stimulated with either LPS 1μg/ml or Lp
(10:1). Supernatants collected 24 post stimulation were analyzed by ELISA for
(A) IL-12, (B) IL-6, (C) IL-1β and (D) TNF-α. The graphs show the mean of four
experiments with SEM.
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LT Treatment is More Toxic than ET in vitro for DCs from BALB/c Mice
The studies in Aim 1 were done using partially purified CD11c+ cell
preparations from BALB/c mice. However, DCs from this mouse strain have
been reported to be sensitive to the toxic effects of LT and because the above
studies showed LT suppressed cytokine production, we measured DC viability in
cells from BALB/c mice and B6 mice which are less susceptible to killing by LT
(3, 48, 90, 142). We also felt it important to study toxin effects in DC
preparations purified by positive selection with anti-CD11c magnetic microbeads.
DCs from both mouse strains were isolated, purified, and treated or not with
either LT or ET, and stimulated with either LPS or Lp infection for 24 hours; the
cells were then incubated with the impermeable, DNA intercalating dye, 7-AAD,
followed by flow cytometry analysis to assess viability. The results showed that
DCs from both strains lose CD11c marker following 24 hours incubation without
GM-CSF (Figure 7, 8, and 9) going from >95% CD11c positive to between 60
and 70% positive after 24 hours. Treatment with LPS alone had no effect on
viability in either strain but LT pre-treated cells from BALB/c mice with LPS
decreased cell viability after 24 hours (Figure 8); viability of cells from B6 mice
was less affected by the LT. Treatment with ET had no effect on viability.
Interestingly, ET treatment did significantly suppress the expression of CD11c in
cells from both mouse strains (Figure 8 and 9). Results with Lp-stimulated cells
showed that infection of the cultures significantly increased CD11c expression
but decreased viability due to the apoptotic effect of Lp (4, 20, 57, 75, 101, 165)
with cells from B6 mice somewhat more sensitive (Figure 9). Treatment with LT
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decreased cell viability even more in cells from BALB/c mice and decreased the
expression of CD11c in cells from B6 mice. ET treatment was not as toxic as LT;
however, overall it decreased the expression of CD11c in both strains as with
LPS-stimulated cells. From these results, it is clear that LT is more toxic than ET
for DCs from BALB/c mice when the cells are stimulated with either LPS or Lp;
however, it appears that ET suppresses CD11c expression in both groups.
Because cells from B6 mice were more resistant to toxicity they were included in
subsequent cytokine studies. In addition, we decided to gate on the CD11c+
cells that were also 7AAD negative in subsequent activation surface marker
studies to determine the toxin effects on viable, CD11c+ DCs.
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CD 11c

DC at 0h
BALB/c

C57BL/6

7-AAD
Figure 7. Magnetic Bead Sorted BALB/c and C57BL/6 Dendritic Cells are
95% Positive for CD11c
DCs from BALB/c and B6 mice were purified by magnetic cell sorting, incubated,
and analyzed by flow cytometry for CD11c expression and viability by 7-AAD
uptake. DCs from both mouse strains were about 95% CD11c+ and viable at the
start of incubation. The data are representative of 3-4 experiments.
38

CD 11c

DC only
BALB/c

LPS

LPS + PA + LF

LPS + PA + EF

C57BL/6

7-AAD

Figure 8. LPS Stimulation: LT decreases cell viability and ET decreases
CD11c
Purified DCs from BALB/c and B6 mice were pretreated for 5-6h with protective
antigen 200ng/ml and either LF 50ng/ml or EF 50ng/ml and then stimulated for
24h with LPS 1μg/ml. The samples were analyzed by flow cytometry for CD11c
expression and viability by 7-AAD uptake. The data are representative of 3-4
experiments.
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CD 11c

DC only
BALB/c

Lp

Lp + PA + LF

Lp + PA + EF

C57BL/6

7-AAD

Figure 9. Lp Infection: LT decreases cell viability and ET decreases CD11c
Purified DCs from BALB/c and B6 mice were pretreated for 5-6h with protective
antigen 200ng/ml and either LF 50ng/ml or EF 50ng/ml and then infected with Lp
10:1 for 50min, washed and incubated for 24h. The samples were analyzed by
flow cytometry for CD11c expression and viability by 7-AAD uptake. The data
are representative of 3-4 experiments.
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LT and ET Can either Enhance or Suppress Cytokine Production in Purified DC
Cultures
Having established that LT was more toxic than ET especially in BALB/c
DC cultures, we re-examined the effects on cytokine production of both toxins in
affinity-purified DC cultures from both BALB/c (sensitive) and B6 (resistant) mice
stimulated with either LPS or Lp. It was hypothesized that cytokine suppression
by LT would be greater in cells from BALB/c mice because of its toxic effect on
these cells. DCs were purified and stimulated for 24 hours and supernatants
harvested and analyzed for IL-12, IL-6, IL-1β, and TNF-α. Figure 10A shows that
for IL-12 production LT was suppressive only in cells from BALB/c while ET was
suppressive in cells from both sources and following both stimuli. For IL-6 (Fig.
10B), LT was suppressive only in BALB/c cells stimulated with LPS, while in cells
stimulated with Lp, the toxin was suppressive in both strains. Since in Figure 8
and 9 we showed that LT is more toxic for BALB/c cells, it is possible that
suppression of IL-12 and IL-6 in BALB/c cells is partly due to the toxic effect of
the toxin. ET treatment moderately suppressed IL-6 following LPS stimulation
but enhanced the cytokine response in cells from B6 mice stimulated with Lp. IL1β levels were surprisingly enhanced in cells from both strains following LT
treatment and LPS stimulation, but were suppressed in both cell groups following
Lp stimulation. ET treatment, on the other hand, had the reverse effect causing a
suppression following LPS treatment and enhancement following Lp stimulation
(Fig. 10C). TNF-α levels were suppressed in all groups by both toxins (Fig. 10D).
It appears from the results that LT and ET could both suppress and enhance
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cytokine production in DC cultures and that this was more dependent upon the
cytokine measured and the cell stimulus than on the mouse strain source of the
cells. LT suppressed cytokines such as IL-12 and IL-6 in cells from sensitive
BALB/c, the toxin could also suppress IL-1β and TNF-α equally in cells from both
mouse strains. Yet it increased IL-1β production from both strains following LPS
stimulation. ET was also surprisingly quite suppressive in cells from both strains,
but it too could enhance select cytokines induced by the two different stimuli
independent of the mouse strain used. Clearly the modulation of cytokine
production by anthrax toxins is dependent on many variables including the
source of the cells, the type of stimulus and cytokine measured, and the
individual toxin tested.

42

Figure 10. LT and ET Differentially Regulate Cytokine Production in Purified
DC Cultures
Affinity-purified DCs from BALB/c and C57BL/6 (B6) mice were pretreated for 56h with protective antigen (PA) 200ng/ml and either LF 50ng/ml or EF 50ng/ml
and then stimulated for 24h with either LPS 1ug/ml or Lp (10-20:1 bacteria to cell
ratio). Culture supernatants were harvested and analyzed by ELISA for (A) IL12p40/p70, (B) IL-6, (C) IL-1β, and (D) TNF-α. Data are the mean ± SEM
cytokine concentrations in culture supernatants from three to four independent
experiments. ♦ p < 0.05, compared to DC only; * p < 0.05, compared to LPS or
Lp only.
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Aim Three: To Determine Toxin Effects on Surface Markers Expression in
Response to LPS and Lp in DCs from BALB/c and C57BL/6 Mice.
LT and ET Differentially Stimulate DC Maturation Marker Expression
The above studies showed that LT and ET can modulate the production of
cytokines associated with immune maturation and polarization of the DCs. To
further examine toxin effects on DC maturation, we examined their effects on DC
maturation marker development following stimulation with LPS and L.
pneumophila in purified, CD11c+ cells from both BALB/c and B6 mice. The
markers studied were those important in adaptive immunity including MHC II,
CD40, CD80 (B7-1), and CD86 (B7-2). Stimulated and toxin treated cells were
stained with fluorescent antibodies and analyzed by flow cytometry. Maturation
marker expression was analyzed on CD11c+ cells that were also viable as
judged by 7-AAD exclusion. Surprisingly, LT greatly increased the expression of
MHCII across both strains and stimuli (Fig. 11A) while ET had a moderate
suppressive effect. Regarding CD40 expression, both toxins suppressed the
response to LPS while, on the other hand, LT increased CD40 expression in Lpstimulated cells (Fig. 11B). Suppression by both toxins was generally observed
across all groups for CD80 marker expression (Fig. 11C); while enhancement of
the CD86 marker was observed except in the case of LPS-stimulated, B6 cells,
where ET significantly suppressed marker development (Fig. 11D). From these
results it appears that LT and ET can either enhance or suppress maturation
marker expression and that this is generally more related to the marker studied
than the cell stimulus or cells source. LT tended to increase MHCII and CD86
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while suppressing CD40 and CD80; and ET on the other hand tended to
decrease all of the markers.

46

Figure 11. LT and ET Differentially Stimulate DC Maturation Marker
Expression
Affinity-purified DCs from BALB/c and C57BL/6 (B6) mice were pretreated for 56h with protective antigen (PA) 200ng/ml and either LF 50ng/ml or EF 50ng/ml
and then stimulated for 24h with either LPS 1ug/ml or Lp (10-20:1 bacteria to cell
ratio). Cells were harvested and analyzed by flow cytometry for (A) MHC class
II, (B) CD40, (C) CD80, and (D) CD86. Data are the mean ± SEM percent
positive of the gated population from three to four independent experiments. ♦ p
< 0.05, compared to DC only; * p < 0.05, compared to LPS or Lp only.
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DISCUSSION

Previous reports have indicated a role of LT and ET in immune
suppression thus facilitating Bacillus anthracis infection and disease (8). A
number of molecular mechanisms for disrupting signaling pathways have been
described for the toxins that can impair the functions of many immune cells,
including T-cells (27, 44, 108), B-cells (45), neutrophils (40, 105, 160),
monocytes (71), dendritic cells (1, 3, 18, 24, 119, 142), and macrophages (12,
31, 42, 111). Dendritic cells are potent antigen presenting cells and play an
important role in innate and adaptive immunity (9, 82, 115, 133). These cells are
now known to have highly diverse characteristics when isolated from various
areas in the host and the characteristics diversify even further when the cells are
stimulated by various microbial antigens. To date, the effect of anthrax toxins on
DC maturation to only two microbial antigens, LPS and anthrax spores, has been
reported. To more fully understand toxin effects, we wanted to study cells
treated with a third type of stimulus, Legionella, a bacterial agent known to infect
and alter DC maturation (84, 85, 121). Our findings show that LT and ET can
either enhance or suppress DC functions, and that the outcome is dependent
upon several factors including the agent used to stimulate the cells, the DC
function tested, and the genetic background of the DC donor mice.
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Dendritic Cells Enrichment by GM-CSF and Incubation Time
Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a potent
immune-stimulating cytokine – secreted by macrophages, T-cells, epithelial cells,
mast cells and fibroblasts – that promotes a strong, long-lasting, systemic
immune response (54). GM-CSF drives stem cells to become granulocytes and
monocytes; and further induces monocytes to maturation upon exiting the
circulation and become macrophages (157).
In 1992, GM-CSF was identified by Inaba et al. to proliferate DC
precursors in mouse blood (60). Shortly after this discovery, the same group
claimed GM-CSF, but not M-CSF, could generate DCs in large quantity from
adherent cells of “stroma” isolated from leg bone marrow (59). In their study,
DCs harvested at day 7 after GM-CSF treatment contained the intracellular
antigens, M342 and 2A1, and the surface antigen 33D1, NLDC145
characteristics of dendritic cells (59). Today, CD11c is recognized as the gold
standard for mouse DCs; however, at 7 days in Inaba’s report the cells were
much less than 100% positive for this marker (59). We therefore examined if
CD11c could be increased by extending the incubation time up to 9 days and
found that the CD11c expression increased with time in the presence of GM-CSF
(10ng/ml). Similar to previous findings (59), we saw a continued reduction in
F4/80 antigen in our cultures as shown in Figure 1. However, along with the
increase in CD11c, the cell number declined significantly beginning on day 8, and
by day 10 only 25% of the cells remained compared to day 7, even when
incubated at a higher (20ng/ml) GM-CSF concentration (data not shown). From
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this, it appears GM-CSF treatment for 7 to 8 days is optimal for the development
of DCs in vitro, a finding supported by previous studies (104). In addition to bone
marrow, GM-CSF is currently used to generate DCs from other tissues including
spleen (83) and liver (114, 139).

Legionella Intracellular Growth Unaffected by Toxin Treatment
There is very little information on the intracellular growth of Lp in DCs.
Although it is known that macrophages from A/J mice (99, 125, 162) do not
restrict the growth of Lp by mechanisms involving deficiencies in phagosomelysosome fusion (50, 149), bone marrow and splenic DCs from these mice
restricted Lp growth (99). In our studies, bone marrow DCs from BALB/c mice
also restricted the growth of Lp (Figure 2). Interestingly, at the same MOI of 10,
the BALB/c DCs ingested 10-fold more Legionella compared to cells from A/J
mice (99); however, BALB/c (and B6) DCs were killed up to 40% as determined
by 7-AAD stain (Figure 9) while A/J DC viability remained constant as measured
by MTT assays (99). These studies demonstrate, that unlike macrophages, DCs
from several different mouse strains restrict the growth of Lp and survive for
several days in spite of the fact that Lp has been shown to induce apoptosis
(165) in macrophages.
It was also important to determine if treatment of Lp-infected DCs with
toxin affected the growth of Lp in our assays because shifting the intracellular
antigen load by toxin treatment could skew DC immune responsiveness as an
indirect consequence of toxin effects. Presumably, Legionella do not express
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the mammalian anthrax-toxin receptors TEM8 (15, 17, 155) and CMG2 (129) and
the coreceptor LRP6 (154); and therefore the bacteria should not be directly
affected by the toxins. However, since anthrax toxins are generally believed to
suppress immune cell function (8), we speculated that Lp intracellular growth
might be affected by toxin treatment. However, this was not the case as seen in
the results from Figure 2. The decrease in Lp colony-forming units was basically
the same in either the presence or absence of LT or ET. Thus, treatment of
infected DCs with the toxins had little effect on the number of intracellular
bacteria per cell culture and therefore little effect on the bactericidal function of
the cells.

Functional Similarity between CD11c Selected and Non-Selected Cells
The cell surface marker that defines a dendritic cell in mouse is the CD11c
marker. This marker is a type I transmembrane protein which belongs to a
member of the leukocyte integrin family (138). Integrins are heterodimeric
proteins which consist of an alpha chain and a beta chain; CD11c is thus
comprised of two subunits, gp150 (CD11c) and gp95 (CD18) (13, 28, 29). In
addition, CD18 associates with two other proteins, lymphocyte functionassociated antigen-1 (LFA-1), CD11a, and macrophage-1 antigen (Mac-1),
CD11b (19, 146). The mouse CD11c antigen is present on DCs in lymphoid
organs (137) and blood, on Langerhans cells in the epidermis (122), on DC
progenitors in the bone marrow, and in-vitro generated bone marrow-derived
DCs (59). In spleen and lymph node, CD11c is expressed at high levels on
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conventional CD11c+CD45R-mPDCA-1- DCs (66, 98, 136, 156), and at moderate
levels on CD11c+CD45R+mPDCA-1+ plasmacytoid DCs (pDC). CD11c is
reported to be weakly expressed on NK cells, B cells, and T cell subsets (133,
139).
The two main functions of the integrins are attachment to the extracellular
matrix (ECM) and to mediate signal transduction from ECM to the cell (58).
CD11c, in particular, binds to complement fragment, iC3b, provisional matrix
molecules (fibrinogen), the Ig superfamily intracellular adhesion molecule (ICAM1, ICAM-2), and also recognizes vascular cell adhesion molecule (VCAM-1)
(124). In addition to cell migration, it has been suggested that this homing
receptor also functions in phagocytosis, cytokine production by monocytes and
macrophages, and induction of T-cell proliferation by Langerhans cells (122,
124). Furthermore, Sadhu et al. have recently suggested a novel role for CD11c
during leukocyte recruitment, antigen uptake, and the survival of DC (124).
Because some of our studies were done with only culture-purified DCs, we
wanted to compare the cellularity and function of these cells versus more highly
purified DCs that were affinity purified for CD11c positive cells. Purification
removed a small cell population, enriched slightly for F4/80+ cells (37 to 47%),
and significantly enriched for CD11c+ cells (52 to 95%) (Figure 5). When
cytokine secretion profiles to stimulation with Lp and LPS were compared (Figure
6), there was really very little difference between the two cell populations
suggesting that although the populations differed by cell size and the expression
of CD11c, they were functionally homogeneous in terms of cytokine production.
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The GM-CSF, culture-purified BM cells contain a small and large population that
were CD11c- and CD11c+, respectively, and we speculate that both populations
when stimulated in culture can mature and function as DCs and that the small
population contain DC precursors. In addition, like in human DCs (133) CD11c
appeared to be an inducible surface antigen the expression of which was
upregulated upon microbial stimulation and downregulated by ET treatment (Fig.
8 and 9). Therefore, the DC precursors can function like mature DCs following
stimulation by microbial products.

LT is More Toxic in vitro for BALB/c than C57BL/6
Several reports showed that LT is more toxic for BALB/c-derived BM-DCs
than for cells isolated from B6 mice (3, 119, 142); and our current results support
these findings. LT toxicity occurred within 24 hours in LPS-stimulated cultures
(Fig. 8); however, in Lp-stimulated cells, LT increased toxicity in BALB/c cells but
had an attenuating effect in B6 cells on the enhanced toxicity induced by this
intracellular pathogen (Fig. 9). On the other hand, in contrast to LT, ET
treatment was not toxic in cultures from either mouse strain. In addition to BMDCs, LT toxicity has also been reported in mouse macrophages (90, 92) and in
DC cultures derived from spleen (1) and lung (24). The mechanisms of toxicity
appear to involve both caspase dependent and independent mechanisms and
also to depend on the extent of activation/maturation of the DCs (3, 119). In fact,
in DCs from B6 mice, LT toxicity was attenuated in matured cells pretreated with
microbial stimuli such as LPS (119). In our studies, the cells were not pretreated
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with LPS but rather with LT followed by LPS for 24 hours; cell damage, as
measured by 7-AAD uptake, increased 8 fold in BALB/c mice while only 4 fold in
B6 mice. Thus, the mouse strain selective toxicity occurred prior to cell
maturation by LPS. In contrast to LPS treatment, our results with Lp-stimulated
cells were quite different, in that as expected, treatment with the intracellular
pathogen was more harmful than LPS for DCs from both mouse strains.
Although LT increased toxicity in BALB/c cells, it surprisingly attenuated the
toxicity in B6 cells. Legionella infection was more toxic in these cells and it is
likely that LT treatment suppressed the intracellular life cycle of Lp and thus its
apoptotic effect (4, 20, 57, 75, 101, 165). Because the LT toxic effect in BALB/c
mice occurred within 24 hours, it is possible that this early toxicity is due to
necrosis rather than apoptosis as suggested by others (3). This cytotoxic effect
has also been correlated with the presence of Kif1c gene (87, 153) and early
necrosis via Nalp1b activation (3, 119).
Studies by Pezard’s group first reported LT, not ET, accounts for the toxin
mortality in mice (112); however, two recent studies showed a significant effect of
ET in whole-animal mortality studies (46, 151). Whether ET is more toxic than
LT in vivo remains unclear; however, we show ET is less toxic on cultured DCs
and this is consistent with other in vitro studies (142). In addition to toxicity, we
show for the first time that ET suppressed the LPS- and Lp-induced expression
of the CD11c lymph node homing receptor (Fig. 8 and 9). This finding is in
contrast to an earlier report showing that CD11c expression was increased 24
hours following phagocytosis of B. anthracis spores (18). This study used human
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monocyte-derived DCs stimulated with attenuated, toxin negative spores, and
these were as potent as fully pathogenic spores in increasing CD11c expression.
Thus, the effect on CD11c in this study probably had little to do with toxin
production. Since CD11c expression may facilitate DC migration to the lymph
node and promote the development of adaptive immunity, it is possible that the
CD11c suppression by ET may prevent effective DC migration and lead to
progression of the infection following spore germination.

Differential Immune Regulation by LT and ET
Cytokine Response
The DC cytokine profile (Figure 10) indicated that production was
differentially regulated by both toxins. In addition, the effect of either LT or ET on
any one cytokine varied depending on the type of stimuli and/or mouse strains.
Our results with LPS- and Lp-stimulated BM-DCs treated with either LT or ET,
support the data of Tournier et al. and Cleret et al. as they observed a similar
type of differential regulation by toxins studies using BM-DC and lung DC,
respectively, stimulated with nontoxigenic (LF-/EF-) mutant anthrax spores RP42
(24, 142). Furthermore, even though there were three related studies examining
the effect of LT on LPS-activated DC in vitro (1, 3, 119), ours is the only study
also investigating the effect of ET treatment on LPS-activated DCs. LT, in
addition to its lethality, was generally suppressive on IL-12, IL-6, and TNF-α in
BALB/c-derived DCs stimulated with either LPS or Lp. This was also seen in
LPS-activated splenic DCs (1) and lung DCs (24) from BALB/c mice. This is
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consistent with the action of LT which is a metalloprotease that cleaves the Nterminus of many MAP kinases responsible for the production of many
proinflammatory cytokines (39, 109, 111, 142, 147). However, in our hands, LT
was not uniformly suppressive. For example, it minimally stimulated IL-12
production in B6 cultures and robustly increased IL-1β in LPS-stimulated cultures
from both mouse strains. The mechanism of this increase is not known at this
time.
ET, though non-toxic in our study, is nonetheless an important factor
contributing to the pathogenesis of anthrax infection and is speculated to work
synergistically with LT (32, 113, 142). We showed that ET suppressed IL-12 and
TNF-α in both BALB/c- and B6-derived DC cultures, which is consistent with the
results from DC stimulated with mutant anthrax spores (24, 142). However, ET
also increased cytokine production such as IL-6 in Lp-stimulated B6 DCs and IL1β in Lp-stimulated DCs from both strains (Figure 10). This enhancement is
similar to that seen in lung DCs stimulated with anthrax spores (24) and human
monocytes stimulated with LPS (56). ET is an adenylate cyclase and increases
intracellular cAMP in target cells thus modulating many physiological processes
(36, 80). It has been shown that elevated cAMP or its analogs contributed to the
increase of IL-6 in human monocytes (56) and the increase of IL-10 in DCs (67)
and splenocytes (55). Our results suggest this ET effect may be extended to the
production of IL-1β in Lp-infected BM-DCs.
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Maturation Marker Expression
In addition to cytokines, we also studied the effect of LT and ET on DC
maturation marker development following stimulation with LPS or Lp. Unlike with
toxin effects on viability and cytokines wherein the source of the cells and the
type of stimulus contributed to the outcome, with marker expression, these
variables had a lesser influence. For example, LT treatment enhanced MHC
class II and CD86 expression across all groups while ET was generally
suppressive across all groups for all of the markers. Our results with LPS are at
variance with those obtained with splenic DCs (1) wherein it was reported that all
markers were suppressed by LT while we saw an increase in MHC class II and
CD86. Other studies with lung DCs infected with anthrax spores or treated with
toxin showed little change in MHC class II and CD86 expression (24) while those
with BM-DCs stimulated with anthrax spores in the presence or absence of toxins
showed an increase in CD86 similar to what we saw.

Speculations on the Mechanisms for Toxin Modulation
Lethal Toxin
Dendritic cells express toll-like receptors (TLRs) on their cell surface to
detect microbial stimuli as well as tissue damage and necrosis (41). LPS
activates DCs through TLR4 which leads to downstream gene activation via
MAPK kinase and/or NFκB signaling cascade (110) as illustrated in Figure 12.
Legionella, on the other hand, activates our DCs through TLR2 and/or TLR9
(103, 121), which ultimately leads to gene activation through MAPKK and/or
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NFκB cascade, albeit slightly different from that of LPS-induced recruitment of
signaling molecules upstream of either cascade. Hence the two activation
pathways are drawn separate in the diagram. This gene activation induced by
either stimulus leads to innate immune response including co-stimulatory
molecule expression and cytokine secretion, all of which define DC maturation
and function, respectively.
Lethal toxin in our study modulates activated DC response in a number of
ways, namely induction of cell death, suppression or enhancement of certain
proinflammatory mediators and maturation markers, and yet there is no effect on
IL-12 and CD80 from B6-derived DCs following LPS stimulation. In terms of
suppression, LF is a metalloprotease (89) that cleaves all members of the
MAPKK family except for MEK5 (161) and disrupts the downstream signaling
(39, 111, 148). Subsequently this leads to gene inactivation and therefore
suppression of markers and cytokines (39).
Consistent with our finding, LT has been shown to induce cell death
particularly in DCs derived from toxin-susceptible BALB/c mice in vitro (24, 142).
There are two possible mechanisms contributing to this toxicity. One, p38 MAPK
has been associated with survival in macrophages (10, 141). We therefore
speculate that disruption of MAPKK upstream p38 may lead to cell lysis. Two,
LF targets the Nalp1b gene which has recently been shown to play a major role
in defining toxin sensitivity in mice (16). Nalp1b protein is a key component of a
very large protein complex called inflammasome (16, 144). The mechanism by
which LF affect this inflammasome is unclear at this time as depicted by the
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question marks in the figure. One function of inflammasome is to activate
caspase-1 and caspase-5 activities (10, 16, 144). And caspase-1 activation has
been associated with apoptosis (119, 144).
The enhancement effect in our study appears to be more dependent on
the type of microbial stimuli relative to the type of mouse strains. LT significantly
increased IL-1β in LPS stimulation; yet its enhancing effect on CD40 was from
that of Lp infection. This LF-induced IL-1β secretion may be associated with
caspase-1 activities because they cleave pro-IL-1 proteins (30). This cleavage
subsequently results in the secretion of the cytokine. In addition, it has recently
been shown that LF may have other substrates, which are likely to contribute to
downstream gene activation (11).
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Figure 12 Mechanisms for Lethal Toxin Modulation
Lp, Legionella pneumophila. LPS, lipopolysaccharide. TLR, toll-like receptor.
MAPK, mitogen-activated protein kinase. NFκB, nuclear factor kappa B. JNK, cJun N-terminal kinase. ERK, extracellular regulated kinase. IL, interleukins.
MHCII, major histocompatibility complex class II. LF, lethal factor.
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Edema Toxin
Similar to the differential regulation by LT, edema toxin can also modulate
the response of activated DCs by promoting their viability, and by suppressing
and enhancing certain cytokine secretion as well as co-stimulatory marker
expression. The basic activation pathway remains the same as previously
described. In terms of suppression, once EF is inside the cytosol and bound to
calmodulin it functions as an adenylate cyclase and increases cAMP
concentration (2, 25, 81). cAMP serves as an intracellular secondary messenger
and can modulate the activity of various cellular process, including neurotransmission, inflammation processes, and water homeostasis (7, 14, 128, 145).
As shown in Figure 13, there are a number of players upstream MAPKK
signaling pathway that can lead to gene activation, such as MAPKK kinase Raf
and GTPase Rho (8, 10, 51). Src kinase is activated by TLR4 which can also
leads to gene activation through accumulation of a number of different proteins
like c-Jun, IRF-1, and CREB (49). The direct molecular target for cAMP is
Protein Kinase A (PKA) (49). The suppression in our study is very much likely
associated with cAMP-activated PKA that then leads to inhibition (49, 67). PKA
can inhibit Raf either directly or indirectly through Ras (8, 10, 51). This inhibition
leads to gene inactivation and ultimately suppression. PKA can also inhibit gene
activation via Rho and Src kinase signaling pathways (8, 10, 51).
In terms of viability, cAMP response element binding protein (CREB) has
been associated with increase in cell viability (10, 49), which may explain why we
observed ET partially helps promote cell survival from Lp-induced apoptosis in
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Figure 9. CREB can either be activated via a PKA-dependent or independent
pathways (134).
ET enhancement effect is dependent on both stimuli and mouse strain in
our study. ET induced IL-6, IL-1β production, and CD86 expression from B6 DCs
following Lp infection. One study has shown that PKA activation can increase IL10 secretion from DC and macrophages via the catalytic subunit from PKA,
which leads to gene activation (Figure 13) (67).
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Figure 13 Mechanisms for Edema Toxin Modulation
Lp, Legionella pneumophila. LPS, lipopolysaccharide. TLR, toll-like receptor.
MAPK, mitogen-activated protein kinase. NFκB, nuclear factor kappa B. JNK, cJun N-terminal kinase. ERK, extracellular regulated kinase. IL, interleukins.
MHCII, major histocompatibility complex class II. EF, edema factor. Ras,
GTPase. Raf, mitogen-activated protein kinase kinase kinase. Rho, GTPase.
Src, proto-oncogene tyrosine kinase. CREB, cAMP response element binding
protein. IRF-1, interferon regulatory factor-1. c-Jun, transactivator. cAMP, cyclic
adenosine monophosphate. PKA, protein kinase A.
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Summary
In conclusion, the modulating effect of anthrax toxins on DC maturation
and function has been reported using culture systems of splenic, lung, and bone
marrow cells; microbial stimulation by anthrax and LPS; and cells from toxin
sensitive and resistant strains. Our results with BM-DCs from both strains and
stimulated with LPS and Lp confirm the relative toxic nature of LT on cells from
BALB/c mice; however, we also show that LT and ET can attenuate DC toxicity
due to intracellular infection by an agent such as Lp suggesting the modulation of
necrosis and apoptosis by anthrax toxins is dependent upon the relative activity
of these processes within the cell. Our results also confirm previous reports that
LT suppresses IL-12, IL-6, and TNF-α in LPS-stimulated DCs from BALB/c mice,
however, we also show for the first time that LT can increase IL-12 in B6 cells
and IL-1β in cells from both strains. LT also increased the expression of MHC II
and CD86 which was not observed in studies using splenic and lung DCs.
Regarding the effect of ET, we showed for the first time that it suppressed the
homing receptor, CD11c, in response to LPS and Lp stimulation, but increased
the production of IL-6 in Lp-stimulated B6 cells as well as IL-1β in cells from both
strains. Together, the data support the conclusion that anthrax toxins are not
uniformly suppressive of DC function but rather modulate function up or down
depending on variables such as the function tested, the stimulus used to activate
the DCs, and genetic variation in innate immune response mechanisms in the
host cell.
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APPENDIX A

Appendix A: Cytokine Profile from Various Multiplicity of Infection
BALB/c BM-DCs enriched with GM-CSF were infected with L. pneumophila at
various concentrations (5:1, 10:1, 20:1, and so on) in 2ml media for 50min, then
washed with HBSS followed by 18h overnight incubation at 37°C, 0.5% CO2.
Culture supernatants were analyzed by ELISA for IL-12 and IL-6. The graphs
show the representative data of 2 experiments with standard deviation.
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Appendix B: Cytokine Kinetics from Affinity-purified DC
Purified BM-DCs from BALB/c mice infected at MOI 20:1 (bacteria to cells) in
<500μl media for 50mins were washed to remove excess bacteria and incubated
for 6, 12, 18, 24, 48, 72h as indicated by the time points on x-axis. DCs only
were collected 18h later. The samples were assayed for secretion of IL-12, IL-6,
IL-1β, and TNF-α by ELISA. The graphs show the representative of two
preliminary experiments with standard deviation.
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Appendix B
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Appendix C: Cytokine Effects Attenuated Using Heated Toxins
BALB/c DCs mice were pretreated for 5-6 h with protective antigen (PA) 200
ng/ml and either LF (50ng/ml) or EF (50ng/ml) or combination (25+25ng/ml),
followed by LPS (1 μg/ml) stimulation for 24h. LF and EF used on the right panel
were heated to 56°C for 35mins prior to their use. Culture supernatants were
harvested and analyzed by ELISA for IL-12, IL-6, IL-1β, and TNF-α. Data are the
standard deviation of cytokine concentrations in culture supernatants from two
independent experiments.
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